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Astrocytes deficient in circadian
clock gene Bmal1 show
enhanced activation responses
to amyloid‑beta pathology
without changing plaque burden
Celia A. McKee1, Jiyeon Lee1, Yuqi Cai1,4, Takashi Saito2, Takaomi Saido3 & Erik S. Musiek1*
An emerging link between circadian clock function and neurodegeneration has indicated a critical role
for the molecular clock in brain health. We previously reported that deletion of the core circadian clock
gene Bmal1 abrogates clock function and induces cell-autonomous astrocyte activation. Regulation of
astrocyte activation has important implications for protein aggregation, inflammation, and neuronal
survival in neurodegenerative conditions such as Alzheimer’s disease (AD). Here, we investigated how
astrocyte activation induced by Bmal1 deletion regulates astrocyte gene expression, amyloid-beta
(Aβ) plaque-associated activation, and plaque deposition. To address these questions, we crossed
astrocyte-specific Bmal1 knockout mice (Aldh1l1-CreERT2;Bmal1fl/fl, termed BMAL1 aKO), to the APP/
PS1-21 and the APPNL-G-F models of Aβ accumulation. Transcriptomic profiling showed that BMAL1
aKO induced a unique transcriptional profile affecting genes involved in both the generation and
elimination of Aβ. BMAL1 aKO mice showed exacerbated astrocyte activation around Aβ plaques and
altered gene expression. However, this astrogliosis did not affect plaque accumulation or neuronal
dystrophy in either model. Our results demonstrate that the striking astrocyte activation induced
by Bmal1 knockout does not influence Aβ deposition, which indicates that the effect of astrocyte
activation on plaque pathology in general is highly dependent on the molecular mechanism of
activation.
The pathological hallmarks of Alzheimer’s Disease (AD)—the toxic accumulation of amyloid beta (Aβ) plaques
and of hyperphosphorylated tau protein into neurofibrillary tangles—have been known to be accompanied by
activated glia for over 100 years1. However, therapeutics aimed at targeting glial functions in AD have yet to gain
traction in the clinical world, mostly because the roles of glia in Aβ or tau aggregation are still poorly understood.
The amyloid cascade hypothesis of AD states that Aβ is likely the initiating factor in the neuroinflammatory
cascade that leads to tau accumulation, neuronal loss, and eventually cognitive decline2–5. Despite setbacks in
anti-Aβ clinical trials6, the amyloid cascade hypothesis is still widely employed in research and clinical settings7,8,
and many treatment strategies are in development that target Aβ a ccumulation9. Thus, exploring roles for glia in
preventing plaque formation and in clearing Aβ may provide a new avenue for therapeutic targets.
The influence of astrocyte activation in AD still remains to be elucidated: it is unclear whether astrocyte activation primarily exacerbates neuroinflammation and hastens pathogenesis, or whether it tips the balance towards
beneficial functions in clearing Aβ and aiding neuronal survival10. These opposing possibilities are reflected in
recent literature targeting astrocytes in AD. Several studies have associated astrocyte activation with increased
plaque load11–13, while others have associated astrocyte activation with decreased plaque load14,15. These reports
make it clear that the various contexts and transcriptional profiles of activated astrocytes participate in disease
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processes in very different ways. Clearly, there is still a need to define astrocyte genes that either reduce or accelerate Aβ pathology, and then to explore how those genes are expressed in different reactive states.
One set of genes that controls astrocyte functions is the molecular circadian clock. The circadian clock
involves transcriptional-translational feedback loops that regulate rhythmic gene expression on a roughly 24-h
basis. The positive arm of the core clock is made up of heterodimers composed of BMAL1 and either CLOCK
or NPAS2, while the negative arm consists of PER, CRY, and REV-ERB proteins16–18. Together, these clock proteins regulate clock-dependent genes such that roughly 43% of protein-coding transcripts in mice exhibit daily
rhythmicity19 and this number increases to more than 80% in p
 rimates20. Due to the wide range of genes controlled by the molecular clock, it is not surprising that the clock interacts with disease processes: AD symptoms
include circadian disruption in both sleep–wake cycle and general activity21–24. Aβ and other disease pathologies
also affect molecular clock rhythms through modification and degradation of clock genes and proteins25,26. Thus,
unraveling the connection between clock-controlled gene expression and AD progression may reveal pathways
amenable to targeting for AD treatment.
An important aspect of the circadian clock is that it is regulated in a tissue- and cell type-specific m
 anner19.
An emerging literature has shown that the circadian clock in astrocytes modulates gliotransmission and transmitter levels27–31, behavioral rhythms27,29,30,32, metabolism33, and n
 euroinflammation34. We have recently reported
the robust cell-autonomous activation of astrocytes by deletion of the clock gene Bmal1, which induces several
activation and inflammatory m
 arkers34. Moreover, we have also shown that deletion of Bmal1 globally disrupts
Aβ interstitial fluid rhythms and exacerbates Aβ plaque burden in the h
 ippocampus35, though the role of astrocyte BMAL1 in this process is unclear. Taken together, these findings suggest that the astrocyte circadian clock
could regulate activation and downstream genes that may influence Aβ generation, deposition, and clearance.
In this study, we deleted Bmal1 specifically in astrocytes and explored how Aβ pathology was altered in two AD
mouse models. This work sheds light on the many astrocyte clock-controlled genes relevant to AD and their
impact on Aβ accumulation.

Materials and methods

Mice. All mouse experiments were conducted in accordance with protocols approved by the Washington
University Institutional Animal Care and Use Committee (IACUC), which is accredited by AAALAC. All experiments were conducted in accordance with all relevant guidelines and regulations and were performed in a
manner consistent with ARRIVE guidelines (https://arriveguidelines.org). Aldh1L1-CreERT2, and Bmal1fl/fl mice
were obtained from The Jackson Laboratory (Bar Harbor, ME; stock #031008 and 007668, respectively) and were
bred at Washington University. APP/PS1-21 mice36 were a gift from Dr. Mathias Jucker (Tubingen, Germany).
APPNL-G-F/NL-G-F mice37 were crossed with Bmal1fl/fl; Aldh1L1-CreERT2+ to generate APPNL-G-F/wt mice. All cohorts
of mice were mixed sex and consisted of Cre+ and Cre- littermates from several breeding cages. All mice were
maintained on a C57BL\6 background and housed under 12-h light/12-h dark conditions. All Aldh1L1-CreERT2
(Cre- and Cre+) were given tamoxifen (Sigma, dissolved in corn oil, 2 mg/mouse/day for 5 days) by oral gavage at 2 months of age to induce Bmal1 astrocyte-specific deletion. All mice were group housed with food
and water available ad libitum. BMAL1 aKO mice were harvested at 5–7 months of age (1 week, 4 weeks, and
12 weeks post-tamoxifen). APP/PS1-21 mice were harvested at 4 months of age (2 months post-tamoxifen) and
APPNL-G-F/wt mice were harvested at 9.5 months of age (7.5 months post-tamoxifen).
Immunohistochemistry.

Mice were anesthetized with an i.p. injection of Fatal Plus pentobarbital and then
perfused with ice cold PBS-heparin. Tissues were harvested and brains were post-fixed in 4% paraformaldehyde
overnight at 4 °C. Brains were then washed with PBS before being cryoprotected in 30% sucrose in PBS at 4 °C.
50 µm sections were made on a Leica freezing microtome and stored in cryoprotectant solution (30% ethylene
glycol, 15% sucrose, 15% phosphate buffer in ddH20) at − 20 °C. On the day of staining, sections were first briefly
washed in PBS. For X34 plaque staining, sections were permeabilized in PBS containing 0.25% triton X-100
(PBSX) for 30 min at room temperature. X34 (stock solution 10 mM in DMSO) was diluted 1:1000 into staining
buffer containing 60% PBS, 40% ethanol, and 0.02 N sodium hydroxide, and sections were incubated in X34
staining buffer for 20 min at room temperature. Sections were then washed in X34 wash buffer containing 60%
PBS and 40% ethanol, and then washed in PBS. Following X34 plaque staining, sections were then blocked and
permeabilized with 3% goat or donkey serum in PBSX and stained with the following antibodies: rabbit antiGFAP (Dako Z0334, 1:5000), rat anti-LAMP2 (EMD Millipore MABC40, 1:1000), HJ3.4b anti-Aβ (lab of Dr.
David Holtzman, 1:1000), goat anti-IBA1 (Abcam ab5076, 1:500), rabbit anti-Bmal1 (Novus Biologicals NB1002288, 1:2000), Topro (Invitrogen T3605, 1:2000).
Sections were incubated in primary antibodies diluted in PBS containing 1% serum and 0.25% triton X-100
and stored on a shaker in the dark overnight at 4 °C. Sections were then washed several times in PBS and then
incubated in secondary antibodies diluted 1:1000 in 0.25% triton X-100 for 1 h at room temperature. Sections
were washed again in PBS. Sections were given final PBS washes and then mounted on slides with Prolong Gold.
For AT8 staining, frozen brain sections were washed three times with Tris-buffered saline (TBS) for 5 min
followed by incubation in 0.3% hydrogen peroxide in TBS for 10 min at room temperature. Sections were washed
three times with TBS for 5 min, blocked with 3% milk in 0.25% TBS-X (Triton X-100) for 30 min, and then
incubated with biotinylated AT8 antibody (MN1020B; Thermo Fisher Scientific) in 1% milk-0.25% TBS-X at 4 °C
overnight. After three washes with TBS for 5 min, the slices were incubated with ABC Elite (Vector PK-6100)
in TBS for 1 h and were visualized using 3,30—diaminobenzidine tetrahydrochloride (DAB) (Chromogen).

Imaging and analysis. For quantification of cortical and hippocampal pathology, slides were imaged on

a Nikon Eclipse 80i epifluorescence microscope equipped with a Hamamatsu Orca-Flash 4.0 digital camera.
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Images were imported into Fiji (Fiji Is Just Image J) for percent area and BMAL1 expression analyses. For BMAL1
quantification within astrocytes, individual astrocyte nuclei were first identified within GFAP/Topro images.
Astrocyte Topro nuclei were included if they were individually identifiable (not clustered) and were surrounded
by GFAP staining. 15 nuclei per image were identified and then scored as either BMAL positive or negative by an
observer blind to genotype. For AT8 tau quantification, stained sections were imaged using a NanoZoomer, and
quantification was performed using Image J percent area and particle count functions. For 3D analysis in Imaris,
z-stacks were taken on a Nikon A1R confocal at 20 × with a step size of 0.5um. Z-stacks were analyzed in Imaris:
3D surfaces were generated for Aβ plaques (X34, detail 0.2um, threshold 700, voxels above 2000um), astrocytes
(GFAP, detail 0.2um, threshold 800, voxels above 50um), and dystrophic neurites (LAMP2, detail 0.3um, threshold 800, voxels above 2000um). Astrocyte-plaque contacts were quantified using a surface-surface colocalization
function to generate a new surface from colocalizing voxels within the astrocyte and plaque surfaces, for which
the volume was quantified as “astrocyte-plaque contact” and was normalized to the plaque volume per image.
Plaque “shell” 3D surfaces were then created using an Imaris XTension function generated at the Washington
University Center for Cellular Imaging. Plaque surfaces were dilated either 30 µm or 50 µm and new surfaces
were generated as 30 µm shells and 50 µm shells. Astrocyte and dystrophic neurite volume within these shells
was calculated using a surface-surface colocalization function that made a new surface from only colocalizing
voxels between a plaque shell and surface of interest (astrocytes or dystrophic neurites).

ELISA assays. Brain cortices were sequentially homogenized in PBS followed by 5 M guanidine. Sandwich

ELISA was performed using antibodies provided by Dr. David Holtzman (Washington University in St. Louis
School of Medicine). Half-well 96-well plates were coated with HJ7.4 (anti-Aβ37–42) at 4 °C overnight. Samples
were diluted in sample buffer containing protease inhibitors and incubated on the ELISA plate overnight at 4 °C.
Aβ42 was detected with a biotinylated HJ5.1 antibody (anti-Aβ13–28) followed by a streptavidin-poly-HRP-40
(Fitzgerald Industries). All ELISA assays were developed using Super Slow ELISA TMB (Sigma) and absorbance
was read on a Bio-Tek Synergy 2 plate reader at 650 nm. Standard curves were prepared from synthetic human
Aβ42 from rPeptide.

Real‑time quantitative PCR.

For RNA extraction from tissue, cortices were placed in Trizol and homogenized using steel beads and a bullet blender (Next Advance). Chloroform was added, and after centrifugation
aqueous phases were collected. RNA was extracted using a PureLink RNA Mini Kit (Life Technologies), and
RNA concentrations were measured on a nanodrop spectrophotometer (Thermo Nanodrop 8000) before storing RNA at −80 °C. cDNA was prepared from RNA samples using a high-capacity reverse transcription kit
(Applied Biosystems). Taqman probes (Applied Biosystems) were combined with cDNA samples and real-time
quantitative PCR was run on either a StepOnePlus or QuantStudio 12 k Real-Time PCR thermocycler (Applied
Biosystems). Data were analyzed using the delta-delta Ct method with Actb or Gapdh as housekeeping genes.

Fluidigm micro‑fluidic qPCR. For Fluidigm micro-fluidic qPCR analysis of gene expression, RNA and
cDNA were prepared as above and sent with Taqman probes to the Washington University Genome Technology
Access Center for high-throughput qPCR on a Fluidigm BioMark HD system. Data were analyzed as described
above.
RNA sequencing and analysis. RNA sequencing and analysis were performed by the Genome Technol-

ogy Access Center at Washington University using their standard methods, which are summarized here. Sample
RNA integrity was determined using a Tapestation and library preparation was performed with 10 ng of total
RNA for samples with a Bioanalyzer RIN score greater than 8.0. ds-cDNA was prepared using the SMARTer
Ultra Low RNA kit for Illumina Sequencing (Takara-Clontech) per manufacturer’s protocol. cDNA was then
fragmented using a Covaris E220 sonicator using peak incident power 18, duty factor 20%, cycles per burst 50
for 120 s. The cDNA was blunt ended, had an A base added to the 3’ ends, and then had Illumina sequencing
adapters ligated to the ends. Ligated fragments were then amplified for 12–15 cycles using primers incorporating
unique dual index tags. The fragments for each sample were then pooled in an equimolar ratio and sequenced on
an Illumina NovaSeq-6000 using 150 base pair paired end reads. Basecalls and demultiplexing was performed
with Illumina’s RTA 1.9 software and the reads were aligned to the Mus musculus Ensembl release 76 GRCm38
primary assembly with STAR version 2.5.1a. Gene counts were quantitated with Subread:featureCount version
1.4.6-p5.
All gene counts were then imported into the R/Bioconductor package EdgeR and TMM normalization size
factors were calculated to adjust the samples for differences in library size. Ribosomal genes were removed and
only genes expressed greater than one count-per-million in at least four samples were kept for further analysis.
The adjusted TMM size factors and the matrix of counts were then imported into the R/Bioconductor package
Limma. Weighted likelihoods were then calculated for all samples and the count matrix was transformed to
moderated log 2 counts-per-million with Limma’s voomWithQualityWeights. Differential expression analysis
was then performed to analyze for differences between conditions and the results were filtered for only those
genes with Benjamini–Hochberg false-discovery rate adjusted p-values less than or equal to 0.1.

Software. Graphs and some heatmaps were generated using GraphPad Prism version 9.2 (https://www.
graphpad.com). The volcano plot in Fig. 1 was generated using R Studio version 1.3.959, using the Enhanced
Volcano package (https://www.rstudio.com), while heatmaps in Fig. 1B,C were generated using Pretty Heatmaps package. Image analysis was performed using Fiji version 2.1 (https://imagej.net/software/fiji) and Imaris
9 (https://imaris.oxinst.com).
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Figure 1.  Brain transcriptomic analysis of astrocyte-specific Bmal1 KO mice. (A–C) RNAseq analysis of frontal
cortex from 5-month-old BMAL1 aKO mice and Cre- littermate controls (3 months post-tamoxifen) reveals
differentially expressed genes defining clock-disrupted astrocytes (n = 5 WT, n = 4 BMAL1 aKO). (A)Volcano
plot of differentially expressed genes in BMAL1 aKO (Log2 fold change cutoff = 1.2, -Log10pvalue cutoff = 0.05).
(B) Heatmap of differentially expressed genes sorted by log2 fold change (FDR < 0.1). (C) DAA and DAM genes
from Habib et al. 2020, only Cst3 is significantly different (FDR < 0.1). (D,E) Fluidigm qPCR gene expression
analysis of WT and BMAL1 aKO mice given tamoxifen for 5 days and harvested 1 week, 4 weeks, and 12 weeks
later (n = 2–4 mice per group, mice 5.5–7 months-old). (D) Heatmap of genes involved in the circadian clock,
astrocyte activation, and Alzheimer’s disease (AD). Two-way ANOVA analysis: c = significant main effect of
Cre genotype, t = main effect of time post-tamoxifen, c*t = interaction effect of Cre and time, = no significance.
(E) Individually plotted gene expression from D. * = p < 0.05, ** = p < 0.005, *** = p < 0.0005, **** = p < 0.0001
by two-way ANOVA with Sidak multiple comparisons test. Panels (A–C) was made using R Studio version
1.3.959 (https://www.rstudio.com), (A) using the Enhanced Volcano package, and (B,C) using Pretty Heatmaps
package. (D) was generated using GraphPad Prism version 9.2 (https://www.graphpad.com).
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Results

In order to elaborate on the astrocyte activation state induced by Bmal1 deletion that we have previously
reported34 and to understand how disease-relevant genes are affected, we performed bulk RNA sequencing on
cerebral cortex tissue from astrocyte-specific Bmal1 knockout mice (Aldh1l1-CreERT2;Bmal1fl/fl), termed BMAL1
aKO) and Cre-;Bmal1fl/fl control littermates at 3 months post-tamoxifen treatment (5 months of age). Similar
to our previous findings from global and brain-specific Bmal1 KO mice, many genes associated with reactive
astrocytosis were significantly upregulated, demonstrating that astrocyte BMAL1 regulates these genes in a cellautonomous manner (Fig. 1B). Based on their reproducibility and fold change across experiments, we find that
the most definitive markers of this activation state are Fabp7, Gfap, Mmp14, and Cxcl5 (Fig. 1B,E).
We considered whether this activation state is transcriptionally similar to an Alzheimer’s disease-associated
astrocyte profile as previously described by Habib et al.38, as this would provide clues to how clock-disrupted
astrocytes may influence Alzheimer’s Disease. However, across genes shared by disease-associated astrocytes
and microglia, we saw no significant differentially expressed genes in our RNA sequencing analysis other than
Cst3 (Fig. 1C), although by real-time qPCR we see a mild increase in Apoe expression in timecourse experiments
(Fig. 1E). We also tested whether BMAL1 aKO fits an A1 or A2 reactive state but did not see any differentially
expressed A1 or A2 genes, only the pan-reactive gene Gfap (data not shown), which matches our previous findings from brain-specific Bmal1 KO mice34. Thus, our data suggests that the Bmal1 astrocyte-specific knockout
phenotype is a unique reactive state with an unknown contribution to brain health and disease.
To further validate these findings and explore the timecourse of the astrocyte activation phenotype, we
treated BMAL1 aKO mice with tamoxifen and harvested mice at 1 week, 4 weeks, and 12 weeks post-tamoxifen.
We then examined expression of genes involved in the circadian clock, the BMAL1 aKO astrocyte activation
phenotype, and Alzheimer’s Disease. In this whole tissue analysis, the overall circadian clock expression was
not remarkably different due to the fact that Bmal1 was only deleted in astrocytes and much of its expression is
in neurons, although Nr1d1 and Dbp were significantly decreased in BMAL1 aKO Cre+ cortices at 1 week posttamoxifen (Fig. 1D, for BMAL1 astrocyte-specific expression see Fig. 5A). For markers of the clock-disrupted
astrocyte activation phenotype such as Gfap, Fabp7, S100a6, and Cxcl5, we found that the upregulation of these
genes develops over time and is most striking at 3 months post-tamoxifen (Fig. 1D,E). Similarly, dysregulation
of Alzheimer’s related genes such as Apoe, Chi3l1, and Mmp14 also appeared most differentially expressed at
3 months (Fig. 1D,E). These data indicate that this activation state is stable, develops over time, and likely interacts
with aging-associated processes.
Our time-course results also indicate that astrocyte BMAL1 regulates genes with conflicting reported effects
on Aβ accumulation. For example, we have previously reported that knockout of the clock-controlled gene
Chi3l1 ameliorates Aβ pathology likely through facilitating Aβ phagocytosis by g lia39. Here, we also found that
BMAL1 aKO markedly reduces Chi3l1 expression (Fig. 1E), indicating that Aβ pathology may be ameliorated
by this astrocyte activation state. Similarly, Mmp14, an Aβ degrading e nzyme40, was highly overexpressed in this
model (Fig. 1E), suggesting increased capacity for Aβ degradation. However, we also found that Apoe expression is mildly increased (Fig. 1E). Increased Apoe expression in mouse AD models has been shown to promote
amyloid plaque formation41,42, suggesting that BMAL1 aKO could lead to elevated plaque burden. In addition,
some of the main genes involved in astrocyte Aβ uptake and degradation such as Ide43–45, Mme43,46, and Lrp147–49
did not significantly change in BMAL1 aKO brain (Fig. 1D,E). As mentioned above, the BMAL1 aKO activation
state also does not appear to overlap with the disease-associated astrocyte phenotype. Therefore, there may be
conflicting effects on Aβ pathology induced by the clock-disrupted astrocyte.
To understand how Bmal1-depleted astrocytes behave in the context of Aβ pathology, we examined astrocyte
activation in the cortex of BMAL1 aKO mice crossed to the APP/PS1-21 model of Aβ-amyloidosis (Aldh1l1CreERT2;Bmal1fl/fl;APP/PS1-21). APP/PS1-21 mice express human amyloid precursor protein and presenilin 1,
both containing AD-associated m
 utations36. These mice develop fibrillar amyloid plaques beginning around
3 months of age. We treated mice with tamoxifen at 2 months of age to induce Bmal1 deletion, then harvested
mice at 4 months, when mild-moderate plaque burden is present. By using 3D reconstruction of X34-labelled
fibrillar plaques and GFAP-expressing reactive astrocytes, we were able to observe and quantify astrocyte reactivity in relation to the plaque environment (Fig. 2A,B). We also quantified astrocyte contacts with plaques by
measuring 3D overlap of GFAP and X34, as well as the volume of GFAP+ astrocyte staining within 30 and 50 µm
“shells” generated around plaques (Fig. 2A,B). Our imaging analysis indicated that the overall GFAP+ astrocyte
volume per image (Fig. 2C), as well as the GFAP+ astrocyte volume within the outer 50 µm shell (Fig. 2B) were
increased in BMAL1 aKO;APP/PS1 mice, as compared to Cre-;APP/PS1 littermate controls. However, the 3D
contact between the plaque surface and astrocytes was not significantly different (Fig. 2B). Notably, images were
selected in this analysis such that the volume of Aβ plaques and peri-plaque dystrophic neurites per image were
the same across Bmal1 genotypes (Fig. 2C). These data indicate that plaque-associated astrocyte activation covers a wider area of tissue in the BMAL1 aKO brain, which may represent an interaction between BMAL1 aKO
and Aβ in inducing astrocyte activation. However, BMAL1 aKO does not influence the physical interaction of
astrocytes with plaques.
To quantify the effect of BMAL1 aKO on Aβ deposition, we first performed imaging analysis of plaque
burden in our BMAL1 aKO; APP/PS1 mice using the X34 stain for fibrillar plaques and an antibody to total
Aβ (HJ3.4b). Surprisingly, while GFAP staining was increased in both the cortex and hippocampus for BMAL1
aKO mice (Fig. 3A), we found no significant difference in fibrillar plaque burden (X34+) or total Aβ plaques
(HJ3.4b+) between Cre-;APP/PS1 and BMAL1 aKO APP/PS1 mice in either region (Fig. 3B,C). Dystrophic neurites (LAMP2) and microglia activation (IBA1) were also unchanged and mirrored plaque burden (Fig. 3D,E).
Phosphorylated tau exhibited some mild signal in these mice, but this was far lower than a conventional P301S
tau mouse and also did not show an effect of Cre genotype (Supp Fig. 1). In addition, we prepared PBS- and
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Figure 2.  Astrocyte-specific Bmal1 deletion increase peri-plaque astrocyte activation in APP/PS1 mice. (A)
Confocal images and 3D renderings of cortical astrocytes and plaques from 4-month-old BMAL1 aKO; APP/
PS1-21 mice and Cre- controls (scale bar = 40 µm). Plaques labeled in blue (X34) and astrocytes labeled in
green (GFAP) with astrocyte-plaque contact represented by 3D overlap (red). Plaque shells rendered at 30 µm
and 50 µm distance from plaque surface. (B) Quantification of astrocyte-plaque contact volume and astrocyte
volume within the outer shell (50 µm from plaque surface). (C) Quantification of 3D plaque volume, dystrophic
neurite volume (LAMP2) and astrocyte volume per 20X image. * = p < 0.05, *** = p < 0.0005 by T-test. Panel 1A
was generated using Imaris version 9 (https://imaris.oxinst.com).

Guanidine-soluble fractions of brain lysates to quantify Aβ levels by sandwich ELISAs. Using an antibody for
Aβ 37–42 (HJ7.4), we also found no difference in either PBS- or Guanidine-soluble fractions between Cre- and
BMAL1 aKO APP/PS1 mice (Fig. 3F). These data indicate that despite a striking dysregulation of Alzheimer’s- and
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Figure 3.  Bmal1 deletion in astrocytes does not affect Aβ deposition in APP/PS1 mice. Images of brain sections
(left) and percent area quantification (right) from 4-month-old old BMAL1 aKO; APP/PS1-21 mice and
Cre- controls stained for GFAP (A), fibrillar Aβ (X34, B), total Aβ (HJ3.4b, C), dystrophic neurites (LAMP2,
normalized to X34 area, D), and microglia (Iba1, E) (n = 6–10 mice per group, scale bars = 500 µm). (F) ELISA
measurements of Aβ 1–42 in PBS- and Guanidine-soluble fractions from cortex (n = 8 mice per group).
* = p < 0.05 by T-test.
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Figure 4.  Bmal1 deletion in astrocytes does not affect Aβ deposition in APPNL-G-F/wt. (A–D) Images of brain
sections from 9.5-month-old BMAL1 aKO; APPNL-G-F/WT knock-in mice and Cre- controls stained for GFAP(A),
fibrillar Aβ (X34, B), total Aβ (HJ3.4b, C), and dystrophic neurites (LAMP2, D) (scale bars = 500 µm).
Quantifications are percent area per cortex or hippocampus. n = 7–8 mice per group. *** = p < 0.0005,
**** = p < 0.0001 by T-test.
activation-associated genes and increased peri-plaque astrocyte activation, BMAL1 aKO does not influence Aβ
plaque burden, dystrophic neurites, or microglial activation in the APP/PS1 model.
We considered the possibility that 2 months of Bmal1 deletion was an inadequate timeframe in which to
observe an effect in the aggressive APP/PS1-21 model, as clock-disrupted astrocyte activation develops over
time (Fig. 1). Thus, we sought to examine the effect of astrocyte Bmal1 deletion in a slower model of amyloid
deposition. The APPN-L-G-F model is an APP knock-in mouse which has been shown to also produce Aβ plaques
at a much slower rate when expressed in a hemizygous f ashion37. As opposed to the 4-month time point for APP/
PS1-21 mice, hemizygous A
 PPNL-G-F/wt mice take closer to 9 months to accumulate a significant number of Aβ
plaques37. We hypothesized that the ability of activated astrocytes to influence Aβ deposition may depend on the
rate of protein accumulation, as seen for astrocyte TFEB activation influencing a slower but not a more aggressive
tau pathology m
 odel50. Thus, we generated BMAL1 aKO mice which were hemizygous for A
 PPN-L-G-F knock-in
(Aldh1l1-CreERT2;Bmal1fl/fl;APPNL-G-F/wt) in order to investigate the role of clock-induced astrocyte activation
in more slowly progressing Aβ pathology. After aging mice to 9.5 months, we harvested them for histopathology and gene expression analysis. Similar to the APP/PS1 model, BMAL1 aKO;APPNL-G-F/wt mice had elevated
GFAP expression in the hippocampus and cortex which extended beyond the immediate vicinity of the plaque
(Fig. 4A). However, the BMAL1 aKO;APPNL-G-F/wt mice also did not show a difference in X34-stained insoluble
Aβ plaque burden, HJ3.4b-stained total Aβ plaque, or LAMP2 dystrophic neurite staining around plaques, as
compared to Cre- littermates (Fig. 4B–D). Our results from these two Aβ pathology models indicate that Bmal1
knockout in astrocytes increases peri-plaque astrocyte activation but does not influence Aβ plaque deposition
or associated neuronal dystrophy.
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We next decided to confirm that the BMAL1 aKO astrocyte activation state is retained long-term in these Aβ
pathology models. It is possible that while Bmal1 deletion initially activates astrocytes, the Aβ plaque environment is a stronger stimulus that shifts astrocytes to a DAA-like or other phenotype and overwhelms any effect
of clock disruption on Aβ deposition. We first checked whether BMAL1 expression in our astrocyte knockout
mice is still reduced in the plaque environment. We performed immunohistochemistry for BMAL1 since neurons
and other cells express high levels of BMAL1 and make astrocyte-specific Bmal1 knockout difficult to detect by
whole tissue methods. By staining for BMAL1 in Cre- and Cre+ APP/PS1 mice, we observed that this knockout reduces BMAL1 within astrocytes by ~ 70% in both the wildtype and plaque-ladened brain (Fig. 5A). We
examined gene expression using Fluidigm micro-fluidic qPCR on cortex tissue from Cre- and Cre+ mice with
and without APP/PS1-21, as well as Cre- and Cre+ APPNL-G-F/wt mice (Fig. 5B,C). Strikingly, the BMAL1 aKO
astrocyte activation was retained in our Aβ plaque models, and for some genes, expression changes were indeed
enhanced by the plaque environment. For example, Fabp7 expression was consistently elevated in all BMAL1
aKO mice independent of Aβ status (Fig. 5B,C). Chi3l1 expression levels also showed a main effect of BMAL1
aKO alone (Fig. 5B,C). On the other hand, Gfap, C4b, and Cxcl5 showed an interaction effect for which the Aβ
models further enhanced their upregulation in BMAL1 aKO mice (Fig. 5B,C). Alzheimer’s-associated gene
expression again showed conflicting results: the Aβ-generating gamma-secretases Psen1 and Psen2 were weakly
upregulated by BMAL1 aKO, mainly in the APP/PS1- littermate controls. Lrp1 was also upregulated by BMAL1
aKO, but this was only significant in the APP/PS1+ mice. Regarding Aβ degrading enzymes, Mmp14 increased
in BMAL1 aKO but was not impacted by Aβ, while Ide showed no changes. Apoe also showed upregulation
in response to BMAL1 aKO, and this was increased in the APP/PS1-21 mouse. Importantly, microglial genes
such as Iba1, Cd68, Trem2, Tlr2, Tlr4, and Tyrobp only changed with Aβ model, mainly APP/PS1, and were not
affected by Bmal1 status (Fig. 5B,C, Supp Fig. 2). These observations demonstrate that astrocyte Bmal1 deletion
alters the astrocyte response to Aβ pathology, leading to synergistic dysregulation of certain BMAL1-regulated
astrocyte genes. The involvement of BMAL1 in both Aβ-generating and Aβ-reducing processes also illustrates
how astrocytes that exhibit an activated profile can still contribute a net-negative effect to Aβ deposition.

Discussion

In its position as an essential core clock gene that regulates a wide variety of gene expression, Bmal1 has the
potential to determine cell-type specific responses to shifts in brain health. Here, we have demonstrated that
Bmal1 deletion dysregulates a range of astrocyte transcripts and induces activation, which is enhanced in Aβ
plaque mouse models. However, BMAL1 aKO neither prevents nor exacerbates Aβ deposition. This curious
observation indicates that it is critical to understand how specific astrocyte genes and functions are regulated in
various activation states in order to interpret their effect on Aβ generation and degradation.
Previous literature has provided some insights into how astrocytes behave in the plaque-ladened brain and
how they may influence Aβ accumulation. Most recently, it has been reported that disease-associated astrocytes
(DAAs) in 5xFAD mice have a transcriptional profile that diverges from GFAP-expressing wildtype a strocytes38.
DAAs express markers involved in endocytosis, the complement cascade, and aging, including a number of
genes linked to Aβ accumulation. In our study, it is likely that some of these processes are altered in BMAL1
aKO, but the gene sets we have identified do not align with those in DAAs. However, it is also worth noting that
some of the “wildtype” GFAP-high defining genes reported by Habib et al., such as Gfap, Aqp4, Apoe, and Fabp7
are significantly elevated in BMAL1 aKO. Thus, Bmal1 deletion induces an astrocyte activation state that may
represent a ”wild-type” activated astrocyte, rather than the plaque-induced DAA profile.
Studies of astrocyte activation states in AD models have not yet definitively determined how activation
impacts Aβ accumulation. Whether activated astrocytes ameliorate or exacerbate disease may depend on the
context and transcriptional profile of their activation. For example, two studies have explored knockout of
the critical astrocyte activation genes Gfap and/or Vim in APP/PS1 Δe9 mice14,51. While one study found that
this method of decreasing astrocyte activation accelerated Aβ pathogenesis and neuritic d
 ystrophy14, the other
found no difference in Aβ plaque load, even though there were several transcriptional changes51. Another study
involved deletion of the astrocyte water channel gene Aqp4 and found increased plaque burden and synaptic
protein damage associated with reduced astrocyte activation, though AQP4 presumably regulates glymphatic
function as opposed to classical astrocyte activation15. These studies contrast with those that have found that
activated astrocytes exacerbate disease: Stat3 knockout or inhibition prevents astrocyte reactivity and decreases
plaque load11,12, as does Clusterin o
 verexpression13.
It is also worth noting that several astrocyte-expressed genes have been shown to specifically regulate Aβ
accumulation, though these genes are not necessarily tied to typical astrocyte activation. For example, Lrp1
expression in astrocytes regulates Aβ uptake and limits plaque f ormation49. It has been suggested that LRP1
shows strong expression in reactive astrocytes around plaques52, but expression of LRP1 in AD patient brains
has yielded conflicting reports, some of which suggest that the overall expression of LRP1 is reduced in A
 D53.
Lrp1 is also not among the DAA g enes38. Conversely, Apoe is primarily expressed in astrocytes and is among the
genes induced in DAAs. APOE secreted from astrocytes may inhibit Lrp1-mediated Aβ uptake54, and generally
promotes plaque accumulation41. In addition, considering that human APOE isoforms drastically differ in their
risk for AD55, the overall levels of APOE potentially generated by reactive astrocytes may have various effects.
Expressing the risk-associated Apoe4 isoform in mice increases Aβ accumulation and reactive a strocytes56, but
Apoe isoforms do not appear to change expression as a result of astrocyte activation57. We also observed reduced
expression of the AD-associated gene Chi3l1, which we expected to increase microglial activation and reduce
plaque burden due to our previous r eport39 However, as these effects were not seen in this study, we suspect that
greater suppression of Chi3l1 over a longer time frame as seen for Chi3l1 knockout mice is required to produce

Scientific Reports |

(2022) 12:1796 |

https://doi.org/10.1038/s41598-022-05862-z

9
Vol.:(0123456789)

www.nature.com/scientificreports/

A

Aldh1l1-CreERT2; Bmal1fl/fl; APP/PS1
CreCre+

Astrocyte Bmal expression

****

150

APP/PS1 APP/PS1 +

100

50

0

GFAP Topro

Cre-

Bmal1

Cre+

B
m
m
c, m
c
c*m
c, m
c, m
c*m
c*m
m
m
c, m
c
c*m
c
c, m
c
m
****
****

****

****

Fold change

Fold change

C

Chi3L1

1.0

0.5

Fold change

0.0

*

****

p=0.09

*

Vol:.(1234567890)

Cre-

Cre+
Ide

2.0
1.5
1.0
0.5
0.0

Scientific Reports |

****

1.5

(2022) 12:1796 |

https://doi.org/10.1038/s41598-022-05862-z

Cre-

Cre+

10

www.nature.com/scientificreports/
◂Figure 5.  Astrocyte Bmal1 regulates genes with conflicting effects on Aβ deposition. (A) Topro, GFAP, and

BMAL1 staining in CA1 hippocampus of 4-month-old BMAL1 aKO; APP/PS1-21 mice and Cre- controls (scale
bar = 100 µm). Arrows indicate astrocyte nuclei quantified as indicated by Topro nuclei surrounded by GFAP
positivity. Blue circles indicate nuclei quantified as BMAL1 negative. Quantification of astrocytes counted as
BMAL1- or BMAL1+ is shown on the right. n = 5 mice per group, **** = p < 0.0001 by two-way ANOVA with
Sidak multiple comparisons test. (B) Heatmap of Fluidigm qPCR analysis of 20 genes involved in the circadian
clock, glial activation, and Alzheimer’s Disease in cortex from Aldh1l1-CreERT2; Bmal1fl/fl mice and Cre- controls
with or without APP/PS1-21 or A
 PPNL-G-F/wt (n = 6–8 mice per group). Two-way ANOVA analysis: c = significant
main effect of Cre genotype, m = main effect of Aβ model, c*m = interaction effect of cre and Aβ model, - = no
significance (all p < 0.05). (C) Individually plotted genes from A. * = p < 0.05, ** = p < 0.005, *** = p < 0.0005 by
two-way ANOVA with Sidak multiple comparisons test. Panel B was made using GraphPad Prism version 9.2
(https://www.graphpad.com).
this reduction in plaque load. Thus, the relationship between astrocyte activation itself and the expression and
function of genes which influence Aβ deposition is not straightforward.
So how might the circadian clock participate in AD? We have mostly focused on changes to Aβ-related genes
and their effect on Aβ accumulation and neuronal dystrophy in astrocyte-specific Bmal1 knockout, but there are
several other clock functions that may alter the course of AD pathogenesis. We have previously reported that
global Bmal1 knockout elevates Aβ plaque burden in the h
 ippocampus35. This was associated with altered soluble
Aβ rhythms in the interstitial fluid, which may be most directly regulated by Aβ release from neurons rather than
other brain cell types. Our results herein suggest that loss of astrocyte Bmal1 does not explain the increase in
plaques observed in global Bmal1 KO mice. Thus, further investigating the contribution of the neuron-specific
clock to Aβ accumulation may uncover one link between clock disruption and AD progression.
In addition, the astrocyte clock may be involved in other aspects of AD pathogenesis not investigated in this
study. Rhythms in locomotor activity are at least partially controlled by the astrocyte clock27,30,32, and it is likely
that activity rhythms affect other daily behaviors such as sleep and feeding. Interestingly, the most highly upregulated gene in BMAL1 aKO is Fabp7, which influences sleep in humans and mice58, as well as long-term memory
in Drosophila59. Thus, further investigation into how astrocytic BMAL1 influences sleep, activity rhythms, or
other astrocyte functions such as gliotransmission may uncover non-Aβ related contributions to AD progression.
In conclusion, it is tempting to reduce the complexity of astrocyte activation in AD down to an overall “good”
or “bad” effect. Our data, when considered with previous studies, suggests that the answer is more complex, and
that astrocyte activation can have different effects on plaque burden depending on the mode of activation and
the resulting transcriptional profile. Our findings show that loss of astrocytic Bmal1 enhances plaque-related
astrocyte activation and alters gene expression but does not alter plaque burden in two different mouse models.
These findings provide insights into the effects of glial circadian clock disruption in AD and provide future
opportunity to define astrocyte activation states at the molecular level that may impart protective, neutral, or
destructive effects in the AD brain.
Received: 17 September 2021; Accepted: 6 January 2022
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